2016 Hematological Malignancies

Tumour control in GHSG trials HD9, HD12, HD15

0.0 0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0

PFS:91% at 5 years

PFS

HD9 C

HD12 A+B

HD15 all

0

12

24

36

48

60

72

Months from randomization

HD9 C HD12 A+B HD15 all Pts. at Risk

431 715 2012

409 669 1848

385 619 1560

374 592 1122

358 543 702

334 447 359

298 282 122